A randomized double blind, placebo-controlled clinical trial with oral n-acetylcysteine in systemic sclerosis patients and assessment of skin blood flow of the hands with laser Doppler perfusion imaging

Oral N-acetylcysteine in the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000114044

Enrollment

Registered

2010-02-03

Start date

2008-08-25

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

analyze the effect of oral N-acetylcysteine on microcirculation by laser Doppler perfusion imaging in systemic sclerosis patients

Interventions

participants will receive capsules with n-acetylcysteine 600 mg three applications per day orally for 4 weeks to be provided by a developer who did not attend the previous steps

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Raynaud phenomenon secondary to systemic sclerosis with pain

Exclusion criteria

smokers and diabetes

Outcome results